drugset

drugset / Trial / NCT01967550

Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)

NCT01967550 ↗

Phase 3 Completed 304 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of diclofenac DDEA 2.32 % in patient suffering from knee osteoarthritis (OA).

Timeline

Start: 2013-10
Primary completion: 2014-05
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Diclofenac	Other / unclassified	2.32 %	—

Indications